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Background: Six implementation research studies in Malawi,
Nigeria, and Zimbabwe tested approaches for improving retention in
care among women living with HIV. We simulated the impact of
their interventions on the probability of HIV transmission during
pregnancy and breastfeeding.
Methods: A computer-based state-transition model was developed
to estimate the impact of the retention interventions. Patient-level
data from the 6 studies were aggregated and analyzed, and weighted
averages of mother-to-child transmission (MTCT) of HIV probabil-
ities were presented. The average MTCT probability of the more
successful interventions was applied to national estimates to
calculate potential infections averted if these interventions were
taken to scale.
Results: Among the total cohort of 5742 HIV-positive women,
almost 80% of all infant infections are attributed to the roughly 20%
of HIV-positive pregnant and breastfeeding women not retained on
antiretroviral therapy. Higher retention in the arms receiving
interventions resulted in an overall lower estimated MTCT proba-
bility of 9.9% compared with 12.3% in the control arms. In the 2
studies that showed a statistically significant effect, Prevention of
MTCT Uptake and Retention (PURE) and Mother Mentor
(MoMent), the difference in transmission rates between intervention
and control arms was 4.1% and 7.3%, respectively. Scaling up
retention interventions nationally in the 3 countries could avert an
average of almost 3000 infant infections annually.
Conclusions: Linking HIV-positive pregnant women to antiretro-
viral therapy and retaining them is essential for addressing the
remaining gaps and challenges in HIV/AIDS care and the elimina-
tion of MTCT. At national level, even modest improvements in
retention translates into large numbers of infant infections averted.
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PMTCT, mathematical modeling
(J Acquir Immune Defic Syndr 2017;75:S233–S239)
INTRODUCTION
The INSPIRE (Integrating and Scaling up PMTCT
through Implementation REsearch) initiative comprised 6
implementation research studies—2 each in Malawi, Nigeria,
and Zimbabwe.1 Each study tested its own innovative
approach to improving retention in HIV care and treatment
of HIV-positive mothers and their children in its prevention of
mother-to-child transmission of HIV (PMTCT) program.
Clinical trials and programs in developed countries have
shown that it is possible to significantly reduce mother-to-
child transmission (MTCT) of HIV, putting virtual elimina-
tion of MTCT within reach. These data inspired the “Global
Plan,” an effort across 21 prioritized countries in sub-Saharan
Africa and India to achieve a MTCT rate of 5% or less among
breastfeeding populations and 2% or less among nonbreast-
feeding populations by 2015.2 Significant progress toward
this goal has been made, with a reduction from 28% in 2009
to 14% in 2014.3 However, the operational realities of
implementing antiretroviral therapy (ART) programs and
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persistent retention challenges have attenuated the potential
impact of expanded treatment access for pregnant and
breastfeeding women and have kept the goal of virtual
elimination just out of reach for many countries. By testing
multiple innovations targeting improvements in service
delivery and retention for HIV-positive women in 6 different
real-world settings, the INSPIRE studies aimed to provide
evidence to inform program design that will bring countries
close to the goal of achieving virtual elimination of MTCT
of HIV.
The primary outcome for the INSPIRE studies was
retention in care among pregnant women and mothers.
Accurate estimates of the impact of these efforts on trans-
mission, measured by the number of newly HIV-positive
infants, are critical for estimating the need for pediatric
antiretroviral drugs (ARVs) and other resources such as the
number of facilities and trained staff. Measures of success in
preventing MTCT are also essential for policy makers and
health care providers to assess the impact of their efforts and
accordingly continue or modify their approach to PMTCT
service delivery. The benefits of retention on ART are well
recognized as beneficial for HIV-positive women in terms of
their own health. The impact of improved maternal ART
retention on ART for their infants is harder to measure; HIV
testing rates of HIV-exposed infants remains low and often
disproportionally, misses the children of women who have
stopped coming to the facility and are more likely to no
longer be on ART.
We developed the PMTCT and Pediatric Impact and
Cost Model in 2010 to inform national health decision
making regarding the elimination of MTCT and ART scale-
up for pregnant women and children, with a focus on country-
level adoption of the World Health Organization HIV
treatment guidelines as they were released and maximizing
the impact with available resources, particularly drugs,
diagnostics, and health workers.4–7 A modified version of
this model was developed to estimate the probability of HIV
infections transmitted from mother to child within the context
of the INSPIRE interventions in Malawi, Nigeria, and
Zimbabwe. The modeled estimates of HIV transmission
allow us to generalize the effect of the interventions in the
INSPIRE studies beyond their current time frames and
beyond the immediate populations of the 6 individual studies
to better understand the potential long-term impact of invest-
ments in interventions to improve retention of HIV-positive
pregnant and breastfeeding women and their infants. Under-
standing what is possible within the 6 studies allows for the
reflection on how many infant HIV infections could be
averted at a broader level if interventions to improve retention
were taken to national scale.
METHODS
We examined the relationship between MTCT and
timing of maternal ART initiation and retention using
a computer-based state-transition model using Markov cohort
simulation to estimate MTCT probability among the cohort of
women enrolled in the 6 INSPIRE studies.8 The study names,
setting, intervention, design, and cohort size are described in
Table 1.9–14
Data Collection
Aggregated patient data from the 6 INSPIRE studies
were merged. Because outcomes and data collection pro-
cesses of each study varied, some assumptions were
necessary to integrate the data and produce comparable
MTCT estimates for each study and overall for the 6
studies. For all INSPIRE studies except PMTCT Uptake
and Retention (PURE) Malawi, we used national averages
of monthly breastfeeding relevant to the study location. On
average, 84% of women were assumed to be breastfeeding
until 12 months postpartum in Nigeria and Zimbabwe, and
97% in Malawi.15–17 The PURE Malawi study estimated
12-month breastfeeding at 33%. Although 33% is much
lower than the 97% national estimate from the 2014 Malawi
Indicator Cluster Survey (MICS), we used the PURE study
breastfeeding data for the PURE analysis because it was
available for this study. Although Promoting Retention
among Infants and Mothers Effectively (PRIME) study also
took place in Malawi, we decided to use the MICS data
rather than use PURE estimates for PRIME, given that
MICS should be the most nationally representative in the
absence of study data.
TABLE 1. Description of INSPIRE Projects
Project Setting Intervention Design
No. of Women
Enrolled
Promoting Retention among Infants and
Mothers Effectively (PRIME)
Malawi Integrated mother–infant pair clinics with
and without text messaging
3-arm cluster randomized
control trial
1350
PMTCT Uptake and Retention (PURE) Malawi Facility-based and community-based peer
support by women with similar experience
3-arm cluster randomized
control trial
1094
Lafiyan Jikin Mata (LJM) Nigeria Continuous quality improvement using
a breakthrough series approach
2-arm cluster randomized
control trial
504
Mother Mentor (MoMent) Nigeria Structured peer support provided by expert
Mentor Mothers
2-arm prospective matched-
cohort study
497
Eliminating Paediatric AIDS in Zimbabwe
(EPAZ)
Zimbabwe Mother support groups 2-arm cluster randomized
control trial
350
Evidence for Elimination (E4E) Zimbabwe Counselling based on CD4 count at the time
of ART initiation
2-arm cluster randomized
control trial
1150
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For studies without complete data for all women through
12 months postpartum, we used the data that were available for
each month of follow-up and assumed the same pattern of
retention for subsequent months as was observed in the last
month of available data. This could have underestimated the
number of infections from that study population if retention
rates in reality continued to decline after data were collected.
For example, Lafiyan Jikin Mata Nigeria observed
women for 6 months postpartum rather than 12 months.
Two of the studies (PURE and PRIME Malawi) had 3
arms, and the other 4 were 2-arm studies. To balance the
comparison between intervention and control groups overall,
we counted the control arms twice for the 3-arm PURE and
PRIME studies, resulting in a total of 8 control and 8
intervention arms.
One of the important underlying assumptions of the
model is that MTCT probability does not depend on prior
obstetric or HIV treatment history.8 For example, the model did
not account for prior pregnancies, age, date of enrollment, or
maternal history with ART. We analyzed the population of
HIV-positive women in each arm as a single cohort passing
through the states at the same time. The ART retention states
were assumed to be mutually exclusive and collectively
exhaustive, meaning that the women must be in a retention
state and could only be in 1 state at a time. Each state was
homogeneous, meaning that every individual in that state had
the same probability of transmission as the other. The women’s
characteristics themselves (ie, age, CD4 count, viral load, years
of HIV infection, or prior pregnancies) were not assumed to
determine the transmission probability; rather, they were
assumed to have the same probability of transmitting HIV to
their infant based on their ART and breastfeeding status.
Transmission Probability Assumptions
In the absence of population-based epidemiological
surveys, the transmission probability estimates of the model
rely on clinical trials, mostly from sub-Saharan Africa, which
were consolidated in 2012.18 Since that time, more recent
evidence from published clinical trials has become available
that builds on the previous synthesis.19–21 Average MTCT
model assumptions were given a proportionate 30% upper
and lower range to help account for uncertainty (Table 2).
Retention as a Proxy for ART Adherence
Each INSPIRE study used a different definition of
PMTCT retention in care for pregnant and breastfeeding
women and their HIV-exposed infants, related to the context
in which the studies were implemented and the interventions
that were tested (see elsewhere in supplement for additional
detail). We assumed that if a woman was retained, then she
was receiving ART and taking the drugs as prescribed. Our
focus is on consistently taking ARVs in contrast to a definition
of retention that could mean that a woman is attending an
appointment as scheduled, picking up her ARVs on time, or
attending a community support group. The focus on taking
ARVs is critical given that this assumption forms the basis of
the modeled transmission probabilities.
Model Structure and Simulation
The model simulates a closed cohort of HIV-positive
women during the pregnancy and delivery period and for 12
months after delivery, capturing MTCT risk over time
(Supplemental Digital Content 1, http://links.lww.com/QAI/
A993). We modeled the intensity (duration of protection
during pregnancy and breastfeeding) of a therapeutic strategy
(maternal ART) to prevent disease transmission, under the
assumption that a more intense strategy (starting ART early
and continuing throughout the entire breastfeeding period)
would reduce the risk of the event of interest (HIV trans-
mission to the infant). Risk probabilities were assigned to
each state, whereby the number of new infant HIV infections
depends on whether the mother is on ART and the duration of
ART protection during pregnancy and delivery.
HIV-exposed infants, as a result of their risk of
acquiring HIV via MTCT during pregnancy, delivery, and
breastfeeding, comprised the cohort of interest. The model
was used to predict the longer-term impact of retention
strategies introduced in each INSPIRE intervention arm.
The model tracked fetuses/infants as they started out HIV-
negative, were exposed to HIV while in utero, during
delivery, and during breastfeeding, accounting for different
probabilities of HIV transmission depending on maternal use
of ART and length of breastfeeding. The time horizon
modeled included the gestational period and 12 months
after delivery.
During pregnancy and delivery, women within the
study control and intervention cohorts fell into 1 of 2 states:
retained or not retained on ART. Here, ART referred to
a triple combination of ARVs and did not include other
interventions such as providing a single dose of maternal
nevirapine at birth or providing maternal azidothymidine
(AZT) during pregnancy. Women retained on ART were
further differentiated into those who initiated ART before the
current pregnancy (eg, were already on lifelong treatment) or
initiated ART for the first time during the current pregnancy.
Among those who initiated ART during the current
pregnancy, there were 4 states depending on the duration of
coverage during pregnancy: those who were on ART for 14
weeks or more before delivery, between 8 and 13 weeks
before delivery, between 4 and 7 weeks before delivery, and
,4 weeks before delivery. The not retained population
TABLE 2. Summary of Transmission Probability Assumptions
by Maternal ART Coverage During Perinatal and Postnatal
Periods Inputted Into the Model
Perinatal
Risk
Probability, %
Monthly Postnatal
Risk Probability, %
ART started before pregnancy 0.2 (0.1–0.3) 0.01 (0.01–0.01)
ART started during pregnancy
$14 wks gestational coverage 1.1 (0.8–1.4) 0.1 (0.08–0.16)
8–13 wks gestational coverage 2.7 (1.9–3.5) 0.1 (0.08–0.16)
4–7 wks gestational coverage 4.9 (3.4–6.4) 0.1 (0.08–0.16)
ART started just before delivery 7.6 (5.3–9.9) 0.1 (0.08–0.16)
Not on ART 19.9 (13.9–25.9) 1.0 (0.7–1.3)
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included women who were on ART during pregnancy but
stopped ART before delivery and those who never received
any ART during this current pregnancy. The latter category
included women who continued to not receive ART during
breastfeeding and those who would later start ART.
The categories of women were static during the
pregnancy and delivery period. They become dynamic during
the postnatal period, when in each month women/infants
within the cohort had the possibility of transitioning from
breastfeeding to not breastfeeding. Exact dates of stopping
breastfeeding were not used. Rather, if a child was breast-
feeding at any time in a month, he or she was counted as
breastfeeding that month. If they stopped breastfeeding in
a particular month, they were considered as not breastfeeding
starting from the first full month when no breastfeeding
occurred. Infants no longer breastfeeding were considered not
at the risk of HIV transmission and were therefore excluded
from the population at risk after breastfeeding cessation.
Breastfeeding women could transition from being retained on
ART to not retained. Women who were not retained on ART
during pregnancy could transition to being retained
during breastfeeding.
Postnatal transmission was calculated using a monthly
probability of transmission based on retention on postnatal
maternal ART during the breastfeeding period, plus the
duration of breastfeeding. As with all estimates of disease
incidence, only those exposed were included in the popula-
tion at risk. In the case of MTCT, all HIV-exposed infants are
at the risk of acquiring HIV while in utero and during
delivery. Only breastfeeding infants not yet infected are at the
risk of acquiring HIV after delivery. At 1 month postpartum,
all children infected during pregnancy/delivery were excluded
from the population at risk, as were those who were not
breastfeeding. The at-risk population was adjusted each
subsequent month to remove infants infected the previous
month and those who stopped breastfeeding, continuing until
the end of the observation period (12 months) or the end of
the risk period (the end of breastfeeding).
Analysis
We explored the probability of HIV transmission in the
prenatal period compared with the breastfeeding period and
compared those retained with those not retained. We assessed
transmission in the integrated control group from the 6 studies
compared with the integrated intervention group from the 6
studies. Given the variation in population size of each study,
we weighted the integrated data results of HIV transmission
probability based on the sample of enrolled mothers in each
study. All analyses were performed with Microsoft Excel,
Redmond, Washington.
RESULTS
ART Profile of Study Participants
Nearly 3000 women were included in both the merged
6-study control cohort (2785) and intervention cohort (2957)
illustrated in Table 3. A relatively large proportion of HIV-
positive pregnant women in each group (26.8% and 19.3% in
control and intervention groups, respectively) were not
retained on ART at the time of delivery. A proportion
(17.7% in the control group and 10.8% in the intervention
group) had actually initiated ART during the current preg-
nancy but stopped taking ARVs before delivery. Some (4.5%
in each group) had started ART before this pregnancy and
stopped before delivery, and some (4.6% and 4.1% in control
and intervention groups, respectively) were not on ART at all
during the pregnancy.
Of women retained on ART at delivery, the greatest
proportion (57.3% in the control group and 60.2% in the
intervention group) initiated ART during that particular
pregnancy (although this would also be influenced by
study-specific inclusion criteria). A smaller proportion
(12.2% and 17.2%, respectively) were already on ART before
the start of the pregnancy. Overall, only 3.7% and 3.2%,
respectively, started in the 4 weeks just before delivery. On
the whole, the profile of maternal ART initiation and stopping
between control and intervention groups is very similar, with
roughly 7% higher retention in the intervention group
(Table 3).
Proportion of Infant HIV Infections According
to Retention Profile
On average, close to 80% of all infections are attributed
to the roughly 20% not retained. Across both cohorts, overall
between 77.3% and 80.6% of infant HIV infections occurred
among women not retained on ART (Table 4). The majority
of women were retained and make up only about one-fifth of
the overall infections.
Probability of MTCT
In this first analysis, the difference in MTCT rates are
estimated for intervention and control arms of all INSPIRE
studies together even if individual studies did not report an
impact on retention in care. The range around the MTCT
estimate at each time point is relatively wide and overlapping,
TABLE 3. Characteristics of Timing of ART Initiation and
Retention Among HIV-Positive Women in the INSPIRE Studies’
Control and Intervention Groups
Control
(n = 2785),
%
Intervention
(n = 2957),
%
Retained at delivery 73.2 80.7
Initiated ART before the start of this
pregnancy
12.2 17.2
Initiated ART during pregnancy 57.3 60.2
Initiated ART just before delivery 3.7 3.2
Not retained at delivery 26.8 19.3
On ART during pregnancy (started before
pregnancy) but stopped before delivery
4.5 4.5
On ART during pregnancy (started during
pregnancy) but stopped before delivery
17.7 10.8
Not on ART during pregnancy 4.6 4.1
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yet the estimates suggest that overall HIV transmission was
roughly 2.4% lower in the intervention group at 9.9% (range,
7.0%–12.8%) compared with the control group at 12.3%
(range, 8.6%–15.9%), as shown in Table 5. Both control and
intervention groups had slightly higher transmission during
pregnancy compared with the 12-month breastfeeding period.
A stark difference in rates between those retained and not
retained is visible, linking directly to the rates of transmission
from the literature used in our model assumptions. The
variability in the retained figures relate mostly to the timing
of ART initiation (before this pregnancy, early in this
pregnancy, or just before delivery), with the longer duration
of ART coverage resulting in lower transmission.
In a second analysis restricted to the 2 studies that
showed significant improvements in retention associated with
their interventions, PURE and Mother Mentor (MoMent), the
average difference in MTCT rates between the intervention
and control arms was 5.7% (range, 4.1%–7.3%).
National-Level Impact of Improved Retention
on ART During Pregnancy and Breastfeeding
In an analysis of national-level impact, we used the
average difference in modeled retention rate (5.7%) from 2
studies (PURE and MoMent). We applied this average
difference to 2015 national estimates of the number of
children newly infected with HIV in the 3 INSPIRE
countries.22 We found that almost 3000 new pediatric
infections could be averted in 1 year across Nigeria, Malawi,
and Zimbabwe if successful retention interventions were
added to existing efforts in each country (Supplemental
Digital Content 1, http://links.lww.com/QAI/A993).
DISCUSSION
Among the total cohort, the majority of new pediatric
infections were attributed to the approximately 20% of HIV-
positive pregnant and breastfeeding women not retained on
ART. Higher retention in all the intervention arms together
resulted in a 2.4% difference in overall estimated MTCT
probability compared with the control. This is probably an
underestimate of potential benefit as the intervention cohort
included mothers and infants of studies where there was no
effect of the interventions tested by the individual studies. In
the 2 studies, however, that showed a statistically significant
effect, PURE and MoMent, the difference in transmission was
marked with an average MTCT reduction of 5.7%. Scaling up
these successful interventions nationally in the 3 countries
could avert a large number of infant infections annually.
Models provide predictions, the accuracy of which
depend on the underlying assumptions and how close they are
to the real world.23 Here, we are modeling changes in rates of
HIV transmission among children as a result of scaling up
programmatic interventions to improve retention among
pregnant women and mothers. Predictions that go beyond
the measured study outcomes may assist with decision
making about further investment in the interventions that
were tested. However, it is critical that the model’s predic-
tions be qualified and explained and thus interpreted with the
understanding that model results are approximations.
The INSPIRE studies implemented interventions to
increase retention in care for improved maternal and infant
health. Study populations included women living with HIV
who were either initiated on ART or already on ART and
those who stopped taking ART during pregnancy and/or
breastfeeding. Our modeling confirms that in 3 countries,
significant successes in terms of disease transmission can be
realized when HIV-positive women receive ART. The studies
TABLE 4. Proportion of Overall HIV Infections Occurring
Within Each Retention Category and Each Risk Period by
Control and Intervention Groups
Prenatal
Proportion, %
Postnatal
Proportion, %
Overall
Proportion, %
Control
Retained 21.2 15.9 19.4
Not
retained
78.8 84.1 80.6
Total 100.0 100.0 100.0
Intervention
Retained 25.8 17.9 22.7
Not
retained
74.2 82.1 77.3
Total 100.0 100.0 100.0
TABLE 5. Modeled Probability of MTCT Among HIV-Positive Women in the INSPIRE Studies’ Control and Intervention Groups
MTCT % (Range)
Control (n = 2785) Intervention (n = 2957)
Difference Between Control and
Intervention Groups
Prenatal 6.8 (4.7–8.8) 5.3 (3.7–6.8) 1.5 (1.0–1.9)
Retained 2.0 (1.4–2.6) 1.8 (1.2–2.3) 0.2 (0.1–0.3)
Not retained 19.9 (13.9–25.9) 19.9 (13.9–25.9) 0.0 (0.0–0.0)
Postnatal 5.5 (3.9–7.1) 4.6 (3.3–6.0) 0.9 (0.6–1.2)
Retained 1.2 (0.9–1.6) 1.2 (0.8–1.5) 0.1 (0.0–0.1)
Not retained 12.2 (8.6–15.9) 12.2 (8.6–15.9) 0.0 (0.0–0.0)
Overall 12.3 (8.6–15.9) 9.9 (7.0–12.8) 2.4 (1.7–3.1)
Retained 3.2 (2.3–4.2) 3.0 (2.1–3.8) 0.3 (0.2–0.4)
Not retained 32.1 (22.5–41.8) 32.1 (22.5–41.8) 0.0 (0.0–0.0)
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all relied on existing health infrastructure and systems, and
they provide a realistic picture of what can be achieved when
retention investments complement existing efforts and the
associated challenges. This is consistent with results from
other countries in sub-Saharan Africa.24,25 Gains from
improving retention among the nonretained may not be as
striking as the effects of ARVs among retained populations,
yet the focus now needs to shift to addressing the needs of
that 20% of the population, contributing a disproportionate
80% of the infections.
The impact of retention interventions goes beyond the
disease transmission that we have modeled here and extends
to other maternal and child health outcomes. ART for HIV-
positive women maintains better health, allows women to
work and pursue their own ambitions, and is valuable to their
lives apart from the benefit for their children. For children,
beyond the HIV diagnosis, HIV-free survival has been shown
to increase among those born to HIV-positive mothers the
longer the period that women were on ART during preg-
nancy.26 Some of the interventions that reported no gain in
terms of retention had effects on other outcomes such as early
infant diagnosis rates and are likely to have an impact on
pediatric ART initiation and longer-term morbidity and
mortality outcomes.
The main limitations of this analysis are the underlying
uncertainty around the epidemiological assumptions and the
uncertainty around the inputs. There is thus uncertainty
around the estimates of MTCT probability reflected as a wide
range. In addition to these inherent limitations of the approach
to modeling HIV disease transmission, we have introduced
additional variability using integrated data from 6 distinct
studies. Each study evaluated the impact of different inter-
ventions and had its own sample size, outcomes, and data
collection methods. Assumptions were needed to standardize
and pool individual study results for the purpose of analyses.
To have a meaningful comparison, we doubled the numbers
coming from control cohorts of the 3-arm PURE and PRIME
Malawi studies, which, for this analysis, could overrepresent
the standard of care in Malawi compared with Nigeria and
Zimbabwe. In the absence of data on breastfeeding practices
among women included in the studies for all except the PURE
study, we assumed patterns similar to the national average,
which may have overestimated or underestimated the per-
centage of women breastfeeding each month. This may be
important because incident infections during breastfeeding
are known to significantly contribute to MTCT of HIV. Given
the challenge of collecting accurate data on women who
seroconvert during pregnancy or breastfeeding, we have not
adjusted for incident infections in this analysis.
At the national level, even modest benefits in retention
translates into large numbers of infant infections being averted.
Investment in retention interventions during the critical phase of
pregnancy and breastfeeding is critical if the protective benefits
of ART on HIV transmission and survival are to be realized.
Drugs available but not taken do not prevent infections or
improve health outcomes. The hard work of linking HIV-
positive pregnant women to ART and retaining them must be
a priority if national and global goals of elimination of MTCT
and maternal and child survival are to be met.
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